News
Moderna is seeking emergency use authorization from the FDA for its Covid-19 vaccine for children 6 months through 5 years of age.
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
StockStory.org on MSN4d
Why Moderna (MRNA) Stock Is Up TodayShares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results